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Abstract 
Tumour molecular profiling by liquid biopsy is being investigated for a wide range of research and 
clinical purposes. The possibility of repeatedly interrogating the tumour profile using minimally 
invasive procedures is helping to understand spatial and temporal tumour heterogeneity, and to 
shed a light on mechanisms of resistance to targeted therapies. Moreover, this approach has been 
already implemented in clinical practice to address specific decisions regarding patients’ follow up 
and therapeutic management. For central nervous system tumours (CNS), molecular profiling is 
particularly relevant for the proper characterization of primary neoplasms, while CNS metastases 
can significantly diverge from primary disease or extra-CNS metastases, thus compelling a dedicated 
assessment. Based on these considerations, effective liquid biopsy tools for CNS tumours are highly 
warranted and a significant amount of data has been accrued over the last few years. These results 
have shown that liquid biopsy can provide clinically-meaningful information about both primary and 
metastatic CNS tumours, but specific considerations must be taken into account, for example when 
choosing the source of liquid biopsy. Nevertheless, this approach is especially attractive for CNS 
tumours, since repeated tumour sampling is not feasible. The aim of our review is, therefore, to 
thoroughly report the state-of-the-art regarding the opportunities and challenges posed by liquid 
biopsy in both primary and secondary CNS tumours. 
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List of abbreviations 
ATRX: Transcriptional regulator ATRX 
BBB: Blood brain barrier 
BM: Brain metastasis 
cfNA: Cell-free nucleic acids 
CDKN2A: Cyclin Dependent Kinase Inhibitor 2A 
CNS: Central nervous system 
CSF: Cerebrospinal fluid 
CTC: Circulating tumour cell 
EGFR: Epidermal growth factor receptor 
EpCAM: Epithelial cell adhesion molecule 
EV: Extracellular vesicles 
H3: Histone 3 
IDH1/2: Isocitrate dehydrogenase 1/2 
MGMT: O6-methylguanine DNA methyltransferase 
MYD88: Myeloid differentiation primary response 88 
miRNA: Micro RNA 
mRNA: Messenger RNA 
NM: Neoplastic meningitis 
NSCLC: Non-small-cell lung cancer 
PCNSL: Primary central nervous system lymphoma 
SOX2: SRY (Sex Determining Region Y)-Box 2 
TERT: Telomerase reverse transcriptase 
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TP53: Tumour protein p53 
WHO: World Health Organization 
 
Introduction 
The possibility of detecting circulating tumour biomarkers in body fluids, including cerebrospinal 
fluid (CSF), has been exploited in routine clinical practice for tumour diagnosis, treatment and follow 
up for a long time.[1-3] Protein markers are commonly used, but this approach does not provide 
information regarding the tumour’s molecular profile.[3] Comprehensive molecular profiling of a 
neoplasm has now been made possible by the analysis of circulating tumour components, and 
specific applications of this approach, which is usually referred to as “liquid biopsy”, are 
exponentially growing for both research and patient care.[4] 
 
Central nervous system (CNS) tumours are an unmet need: outcome is often dismal, and therapies 
offer limited efficacy. Tumour molecular profiling is especially relevant in this setting as the CNS is a 
peculiar anatomic and functional compartment; even biopsy can carry significant risks. Thus liquid 
biopsy could fulfil its potential in this setting. However, CNS specificities apply to liquid biopsy too. 
For example, the blood brain barrier (BBB) hinders the circulation of tumour components from the 
CSF to the blood, thus potentially impairing CNS tumour sampling through the commonly used 
blood-based approaches. 
 
Over the last few years, a significant amount of data has been accrued regarding liquid biopsy in 
both primary and secondary CNS tumours. The aim of our review is to thoroughly report the state-
of-the-art regarding the opportunities and challenges posed by liquid biopsy in this setting. 
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The role of blood brain barrier 
Although blood is an ideal, easily accessible source for liquid biopsy sampling and is routinely used to 
identify many tumour types, data show that its sensitivity can be severely limited when dealing with 
CNS neoplasms. The main factor hampering the detection of CNS tumour components in blood is the 
BBB. The latter is a peculiar anatomic and functional structure aimed at regulating the traffic of 
molecules and cells into and outside of the CNS. Its functions rely on the synergic activity of a wide 
range of partners including endothelial cells, pericytes and astrocytes.[5] In particular, the 
widespread presence of tight junctions allows the passage of very small molecules only (less than a 
few nanometres) and this could explain the overall poor sensitivity observed by blood sampling 
when looking for components derived from CNS neoplasms.[6] 
As will be discussed, however, in specific situations it seems to be possible to detect the molecular 
signatures of CNS tumours in blood. For example, larger tumour volumes and presence of contrast 
enhancement were correlated with an increased sensitivity for IDH1 mutations.[7] This result can be 
understood if we consider that contrast enhancement is a sign of BBB leakage, which is usually 
associated with higher grade tumours. 
To overcome this limitation, CSF seems the best alternative source for CNS neoplasms considering its 
direct contact with CNS structures. Present data suggest a higher sensitivity of CSF compared with 
blood (Figure 1). Nevertheless, CSF sampling is not free of risks especially for patients with CNS 
neoplasms, although it is usually a feasible and safe approach. 
A different approach would be to alter the BBB permeability to allow the transfer of tumour-derived 
markers into the blood. Until recently, this research topic was mostly aimed at increasing drug 
penetration into the CNS[8]. However, it is now being investigated as a tool to increase the 
sensitivity of liquid biopsy for CNS tumours, for example, using focused ultrasound enabled blood-
based liquid biopsy in animal models of glioblastoma.[9] The specific mechanisms through which the 
BBB hampers the transfer of specific tumour components deserve further study. 
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Last, it should be remembered that the BBB plays an active role in facilitating or preventing brain 
metastases (BM) from systemic tumours. Primary tumour cells can impair the BBB by releasing 
specific molecules such as nucleic acids or proteins, thus increasing the risk of BM development. 
Improved understanding of these mechanisms could pave the way not only to early detection of BM, 
but could also allow risk prediction or prevention.[10] 
 
Technical considerations: what to analyse and how 
The number of potential technical approaches is both extremely high and rapidly evolving.[4] The 
first choice is about which tumour component or marker would be the most informative in the 
specific clinical setting (Figure 2). Analysis of circulating cell-free nucleic acids (cfNA), including 
cfDNA and cfRNA, is the most used approach for the time being, potentially allowing the detection of 
somatic mutations, insertions, deletions, copy number variations and also enabling assessment of 
methylation status and of regulatory nucleic acids, such as microRNAs (miRNA) or long non-coding 
RNAs (lncRNA). These data are what usually matters the most to the pathologist and the clinician to 
achieve a diagnosis and molecular profiling for clinical management. Conversely, cfNA analysis does 
not allow reliable assessment of RNA expression, but this limitation can be overcome by analysing 
circulating tumour cells (CTCs) or extracellular vesicles (EVs) which also allow proteomic studies.[11, 
12] 
Another important choice regarding genomic studies is whether to use a candidate gene strategy or 
larger scale approaches like whole exome sequencing. In the diagnostic clinical setting, the first is 
usually advised: i) it allows reliable assessment of a specific set of genes with known diagnostic 
and/or predictive value; ii) it enables very low limits of detection; iii) it provides a faster, clinically-
suitable, turnaround time with lower costs; iv) bioinformatic support is usually not required; v) 
germline DNA analysis and its ethical/legal implications can usually be avoided. Conversely, for 
exploratory/research studies, extensive approaches, also including deep sequencing, can be 
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considered. Among candidate gene analyses techniques, droplet digital PCR allows an extremely low 
limit of detection (0.001%) and provides precise DNA copy number quantification,[13] thus allowing 
monitoring of residual disease. 
For CTCs and EVs analysis, different strategies have also to be used for primary and secondary CNS 
tumours since these tumour components have to be selectively captured and enriched; the 
proposed approaches will be discussed in the relevant paragraphs. A further informative component 
worthy of mention are circulating platelets. Analysis of tumour educated platelets by RNA 
sequencing has been proven to be highly informative in both primary and secondary CNS 
neoplasms.[14, 15] 
 
Liquid biopsy in primary CNS tumours 
Molecular profiling is of paramount importance for the characterization of primary CNS tumours. For 
this reason, the latest WHO classification of these tumours introduced the concept of “integrated 
diagnosis”: a diagnosis based upon the integration of both morphological and molecular findings. 
This approach is necessary to distinguish between entities with significant biological and clinical 
differences, but overlapping histological features.[16]  
Even considering just the group of diffuse gliomas, a wide range of molecular alterations is relevant 
for their proper classification and treatment: IDH1/2, ATRX, TP53, TERT promoter and histone H3-
coding genes mutations, 1p/19q chromosomal arms codeletion, EGFR alterations and MGMT 
promoter methylation.[16, 17] Overall, specific molecular hallmarks are relevant for diagnosis of 
most primary CNS tumours, while assessment of temporal molecular heterogeneity could help shed 
a light on mechanisms of resistance to treatments. Thus, liquid biopsy could be extremely useful for 
the diagnosis and follow up of primary CNS tumours. 
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Circulating cell-free nucleic acids analysis 
Analysis of the circulating cfDNA shed by tumour cells allows detection of gene alterations, including 
mutations or fusions, changes in methylation profile, copy number variations, and to quantify 
tumour burden; moreover, overall cfDNA (i.e. tumour and non-tumour derived) concentration has 
been suggested to play a prognostic role in primary CNS tumours.[18] 
 
Boisselier et al. (2012) evaluated the detection of IDH1 mutations in plasma cfDNA of patients with 
histologically-proven glioma with known tumour IDH-status:[7] sensitivity and specificity were 60% 
and 100%, respectively (Table 1). Sensitivity correlated with tumour volume and contrast 
enhancement: a higher contrast-enhancing tumour volume was associated with higher sensitivity. 
More recently, Bettegowda et al. (2014) investigated the possibility of detecting a wide range of 
alterations in a large series of tumour types by analysis of plasma cfDNA by digital PCR.[19] A cohort 
of 41 primary brain tumours (including gliomas and medulloblastomas) was also included and, unlike 
most extra-CNS tumours, the detection rates were limited (<50% for medulloblastoma and <10% for 
gliomas). 
The possibility of using CSF as a source for cfDNA analysis in primary CNS tumours was suggested 
more than 20 years ago by Rhodes et al. who identified EGFR amplification and a TP53 mutation in 
glioblastoma patients (Table 1).[1, 2] De Mattos-Arruda et al. (2015) further showed that CSF-
derived cfDNA analysis detects mutations of both primary and secondary brain tumours.[20] 
Regarding the primary neoplasms, 4 glioblastomas and 2 medulloblastomas were investigated; at 
least one tumour mutation was detected in all cases by CSF cfDNA analysis, while blood-derived 
liquid biopsies were negative. Tumour burden, assessed by cfDNA quantification, mirrored the 
neuroimaging findings, thus supporting liquid biopsy as an effective tool to track tumour evolution 
over time and possibly anticipate recurrence/progression, although specific prospective studies are 
needed for clinical validation. Pentsova et al. (2016) confirmed the usefulness of CSF liquid biopsy, 
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but observed a low sensitivity (6/9 patients, 66,7%) in a series of primary CNS tumours, mostly 
including grade III-IV (WHO) diffuse gliomas.[21] 
Tumour variables, such as histological type, grade and site, could influence the efficacy of cfDNA 
analysis. Medulloblastoma, for example, a malignant cerebellar tumour with high cellularity could be 
expected to more easily shed cfDNA into CSF compared to hemispheric diffuse low-grade gliomas 
with an infiltrative growth pattern. This hypothesis is supported by Wang et al. (2015) who found 
that tumours closer to CSF spaces have a higher probability of being detected by CSF cfDNA analysis 
compared to tumours not in contact with the ventricles.[22] This finding was true for different 
tumour types, including high-grade gliomas, ependymomas and medulloblastomas. Interestingly, 
Connolly et al. (2017) analysed matched CSF and blood samples of three cases of grade II 
intramedullary ependymomas without identifying any alteration in blood or in CSF[23]. In this 
regard, other variables such as CSF flow alterations may affect cfDNA circulation and liquid biopsy 
sensitivity. 
A very recent study specifically investigated a large series of diffuse gliomas (n=85), including 46/85 
(54%) glioblastomas and 39/85 (46%) lower grade gliomas (grade II-III), using a targeted next 
generation sequencing-based assay.[24] CSF was collected by lumbar puncture in most cases (82/85, 
96%). Overall sensitivity was of 49.4% (42/85): 59% (27/46) in glioblastomas and 38% (15/39) in 
lower grade gliomas, although a significant association between tumour grade and CSF ctDNA 
detection was not found. Conversely, the presence of ctDNA was associated with tumour 
progression, a higher tumour burden, tumour spread in the ventricular system/subarachnoid space 
and a shorter survival time since CSF collection. This latter finding was found to be independent of 
tumour burden. Regarding the diagnostic efficacy of this approach, in a subset of 10 lower grade 
gliomas with available tissue sample, the genetic alterations currently used to define the glioma 
subtype according to WHO criteria were always consistent between CSF and tissue. Plasma was 
analysed in 19 cases with positive CSF ctDNA and no mutations were detected in most of them 
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(16/19, 84%), while in the remaining samples the mutant allele frequencies were very low. An 
important finding regarding tumour heterogeneity was that, as the time between tissue and CSF 
sampling increased, a greater genetic divergence was observed, in particular for genes involved in 
growth factor signalling pathways. These data highlight the importance of longitudinal molecular 
evaluation in diffuse gliomas and show that liquid biopsy may successfully fulfil this need. 
EGFR alterations are another relevant molecular hallmark since EGFR amplification and/or EGFRvIII 
variant are present in many glioblastomas[25, 26] and have been targeted in many clinical trials 
employing a wide range of strategies (i.e. direct inhibition, vaccination, antibody-drug conjugate 
therapy). Unfortunately, the results have been unsatisfactory so far,[27] but new strategies are 
currently under investigation.[28, 29] Salkeni et al. (2013) were able to detect EGFRvIII in plasma-
derived cfDNA of 3/3 patients with EGFRvIII-positive tumours (out of a cohort of 13 glioblastomas), 
making this marker potentially assessable through liquid biopsy.[30] 
Regarding the diagnostic potential of CSF cfDNA analysis, evaluation of a selected panel of molecular 
alterations in CSF cfDNA allowed the identification of tumour molecular alterations in 17/20 (85%) 
cases of diffuse gliomas, allowing their classification according to the latest WHO criteria.[31] Also 
detection of mutations affecting histone H3 genes in a case series of paediatric brain tumours 
showed high sensitivity and specificity: 87.5% and 100%, respectively.[32] This finding is especially 
relevant as the H3 K27M mutation characterizes, although not exclusively, a subgroup of highly-
malignant midline diffuse gliomas, usually occurring in children. Considering the location of these 
tumours, which often involve the brainstem, this approach could enable to achieve a specific 
diagnosis without the potential risks of a surgical biopsy. 
Recent data further support the sensitivity of liquid biopsy for brainstem gliomas: Pan et al. (2018) 
evaluated a series of 57 patients and were able to detect at least one tumour-specific mutation in 
82.5% (47/57) of cases.[33] Sensitivity reached 96.3% (36/37) when considering only patients with a 
detectable mutation in the tumour tissue sample, while in 83% (31/37), it was possible to achieve 
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the same results as tissue analysis by liquid biopsy. CSF and plasma cfDNA were compared in 8 
patients producing sensitivities of 100% and 37.5%, respectively. Higher levels of cfDNA, tumour 
directly abutting the CSF spaces and higher tumour grade were associated with an effective liquid 
biopsy, while a trend was observed for higher tumour volumes. An important consideration is that in 
most cases (91.2%, 52/57), CSF was collected intraoperatively, thus results could differ from lumbar 
puncture sampling. Last, in 3 cases out of 10 with negative tissue analysis, mutations were detected 
in cfDNA. This result could support the capability of liquid biopsy to capture tumour heterogeneity, 
but it must be interpreted cautiously since sequencing depths differed significantly between the two 
assays. Another recent study by Panditharatna et al. (2018) focused on midline gliomas and 
evaluated H3 K27M mutations and typical partner alterations in cfDNA by droplet digital PCR.[34] 
CSF analysis sensitivity reached 87% (20/23) in H3 K27M-mutant cases (defined through tissue 
analysis), but, interestingly, plasma sensitivity was very high, ranging from 90% (18/20) in the 
original series to 80% (16/20) in a prospective cohort collected during a clinical trial. However, 
mutant allele fractions were lower compared to CSF. The relationship between sampling site and 
mutations detection was also evaluated: a higher mutant allele frequency was observed if CSF was 
collected adjacent to the tumour location, but mutant alleles could be potentially detected in all 
sample sites. Notably, longitudinal comparisons showed a correlation between clinical course, 
radiological findings and mutant allele frequencies. 
A concluding remark regarding the use of liquid biopsy as a diagnostic tool for gliomas is that 
particular care should be applied when selecting the gene panel to be assessed, since dramatic 
differences exist between the molecular landscapes of adult and paediatric tumours. Moreover, 
reliance on single markers should be avoided. For instance, the H3 K27M mutation, which was 
initially considered as a potential pathognomonic alteration of malignant diffuse brainstem glioma, 
has been reported in a wider range of tumours.[35] 
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Liquid biopsy could be useful for diagnosis and follow up of non-glial primary brain tumours as well, 
although less data is available.[36] Hiemcke-Jiwa et al. (2018) demonstrated the possibility of 
detecting MYD88 mutations, a common alteration of primary central nervous system lymphomas 
(PCNSL) (Table 1).[37] This is especially intriguing considered that PCNSL are usually extremely 
chemo/radiosensitive, thus surgery could be avoided. 
Epigenetic alterations are also relevant biomarkers in primary brain tumours. The possibility of 
assessing MGMT promoter methylation in blood-derived cfDNA was first reported by Weaver et al. 
(2006) in a small case series of high-grade diffuse gliomas, achieving a 50% sensitivity.[38] Lavon et 
al. (2010) and further studies confirmed this possibility and also explored the correlations with 
outcome and longitudinal evolution during disease course.[39-41] cfDNA methylation analysis has 
also been proposed for diagnostic purposes in gliomas using CDKN2A promoter methylation 
assessment.[42] 
Analysis of circulating micro RNAs (miRNAs) is another potential strategy. miRNAs are non-coding 
short RNA regulatory molecules, which can widely affect transcription and translation. Most 
available data relate to diffuse glioma, in particular glioblastoma, and a broad range of miRNAs have 
been investigated, alone or in specific combinations, as possible diagnostic or prognostic 
biomarkers.[43-52] Both CSF[44, 45, 49, 51] and blood[43, 46-48, 50, 52] have been evaluated as 
sources of genetic material. The possibility of distinguishing between primary and secondary CNS 
tumours by miRNA profiling, and of estimating patients’ outcome based on their concentrations has 
been suggested. 
Overall, the main limitation of this approach is the heterogeneity of the reported data. Although 
many different candidate miRNAs have been proposed, their validation in larger cohorts is lacking, 
hampering translation into clinical practice. 
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Last, the possibility of exploiting other nucleic acids such as long non-coding RNAs or mitochondrial 
DNA should also be taken into consideration.[53, 54] 
 
Circulating tumour cells 
Circulating tumour cells (CTCs) analysis is another potential approach for liquid biopsy and allows the 
assessment of nucleic acids, including mRNAs, which are usually quickly degraded in the circulation, 
and other tumour cell components such as cytoplasmic proteins. Detection and capture of CTCs is 
challenging due to their extremely low concentration in blood, thus many different techniques have 
been investigated.[55] Moreover, primary CNS tumour cells do not express a common membrane 
marker, thus hampering their detection and collection. 
 
The presence of CTCs from blood in primary CNS tumours was debated due to the extremely low 
incidence of extra-CNS metastases [56]. However, blood CTCs were successfully detected in a series 
of 33 glioblastomas using a combination of markers (SOX2, Tubulin beta-3, EGFR, A2B5, and c-MET) 
with a sensitivity (defined as the rate of patients with at least one positive sample) of 13/33 
(39%).[57] Specific probes for molecular hallmarks of glioblastoma, such as telomerase activity have 
been also investigated. MacArthur et al. (2014) observed a sensitivity of 8/11 (72%) in a series of 
grade III and IV gliomas sampled before radiotherapy.[58] Interestingly, sampling after radiotherapy 
was successful in only 1/8 (12.5%). Müller et al. (2014) were able to detect circulating neoplastic 
cells in 21% (29/141) of patients with glioblastoma by GFAP immunostaining of mononuclear 
circulating cells.[59] Moreover, an integrated positive and negative selection approach was also 
effective in grade II diffuse gliomas reaching a sensitivity of 82% (9/11) in this specific subset of 
tumours. Using this assay, CTCs count resulted associated with tumour status (i.e. progression versus 
radiation necrosis) in an additional series of 5 cases.[60] The significant variability in terms of 
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detection rates is likely due to the differences in technical approaches and to the overall low sample 
sizes. Further larger studies are warranted to confirm the real efficacy of the different analytical 
methods. 
Last, an interesting observation regarding tumour heterogeneity was reported by Sullivan et al. 
(2014): CTCs can show a different gene expression profile compared to the previously resected 
tumour sample. Specifically, increased mesenchymal differentiation and a reduced neural-like profile 
was observed. These data suggest that a single approach or a single set of markers may be unable to 
fully sample tumour heterogeneity.[57] 
 
Tumour educated platelets 
Analysis of circulating platelets is another intriguing approach to achieve liquid biopsy of CNS 
tumours.[61, 62] Many biomolecules are transferred between tumours and platelets and this 
process has been termed platelet “education”.[63, 64]. As initially shown by Nilsson et al. (2011), 
platelets can sequester tumour-shed extracellular vesicles which allow detecting of tumour-derived 
biomarkers, including proteins and nucleic acids like the EGFRvIII mRNA, with high sensitivity and 
specificity.[14] Different patterns of mRNA expression were also observed in platelets of patients 
with glioblastoma compared with healthy controls. The shaping of platelets mRNA splicing by the 
external environment can thus be exploited for tumour diagnostics and profiling. Indeed, Best et al. 
(2015), showed that analysis of RNA splicing profiles of tumour educated platelets was able to 
identify patients with tumours and further distinguish those with localized or metastatic disease. In 
particular, this approach correctly classified 85% (33/39) of patients as patients with a neoplasm in a 
series of 39 glioblastomas. Regarding the specific diagnostic potential, 78% of glioblastoma patients 
were correctly classified when compared with controls and five other tumour types in a training 
series of 175 samples. Similar results were observed in a validation set of 108 cases. Furthermore, in 
a series of 114 samples (62 patients) with brain lesions, tumour educated platelet analysis allowed 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
correct identification of cancer patients in 91%, discrimination between primary and secondary 
tumours in 93% and discerned between the mutational subtypes in 82%.[15] It has also to be 
remembered that blood components can actively promote glioma growth and malignancy, thus 
further studies investigating strategies to antagonize this cross-talk are warranted.[65]  
 
Extracellular vesicles and other approaches 
Extracellular vesicles (EVs) are a heterogenous range of membrane-bound carriers secreted or shed 
by both normal and neoplastic cells. Many studies have investigated their physiological role in 
intercellular communication, which can occur between different tissues or compartments.[66]  
Similar to CTC, liquid biopsy by EVs analysis offers some advantages over cfNAs, allowing mRNAs 
characterization and evaluation of cytoplasmic proteins.[67] In primary brain tumours, this approach 
has been mainly investigated in malignant gliomas, and both blood and CSF have been explored as 
potential sources of EVs. As initially shown by Skog et al. (2008),[11] EVs shed by glioblastoma 
contain a wide range of molecules, including nucleic acids and proteins, and can significantly affect 
distant cells, for instance by increasing proliferation or angiogenesis. Moreover, specific molecular 
hallmarks of gliomas can be detected in EVs: for example, Skog et al. (2008) were able to detect 
EGFRvIII in EVs of 7/25 (28%) patients with glioblastoma. [11] 
More recently, Chen et al. (2013) detected IDH1 mutations in CSF-derived EVs of patients with IDH-
mutant gliomas using highly-sensitive techniques; conversely, serum-derived EVs of the same 
patients were negative.[68] Although based on significantly different approaches and techniques, 
these results somehow conflict with data reported by Boisselier et al. (2012)[7] and indicate the 
importance of further research evaluating how the interplay between biological and technical 
variabilities can affect the results. EGFR alterations can also be assessed in EVs. [11, 69] 
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Concerning immune system evasion, a recent study identified PD-L1 in glioblastoma-derived EVs and 
presence of this ligand was associated with impaired T cell activation.[70]  
miRNAs are another cargo of EVs through which they can exert their regulatory functions on distant 
tissues.[71-73] As for circulating free miRNAs, many candidates have been investigated as potential 
diagnostic biomarkers and different subsets of EVs have been compared.[74, 75] A panel of three 
miRNAs (miR-21, miR-222 and miR-124-3p), detected in blood-derived exosomes, was recently 
shown to be differentially expressed in high grade gliomas compared with low grade gliomas or 
healthy controls.[76] 
Last, circulating proteins and metabolites can be also exploited as biomarkers of neoplastic diseases, 
including brain tumours. The improved knowledge of tumour molecular profiles and their correlation 
with cellular metabolism could enable new avenues for diagnosis and monitoring of CNS neoplasms, 
as recently shown by Ballester et al. (2018).[77] This extensive topic, however, is outside the scope 
of the present review. 
Liquid biopsy in secondary CNS tumours 
Brain metastases are the most frequent intracranial tumours. They develop in 9-17% of patients with 
solid tumours (usually from lung and breast cancers and melanoma) and their incidence is 
increasing.[78, 79] Quality of life and outcome are severely affected by BMs[80], but encouraging 
results have been recently achieved thanks to targeted therapies and immunotherapeutic drugs.[81]  
BMs from solid tumours often show a divergent molecular profile compared to the primary lesion. 
Spatial and temporal heterogeneity is an intrinsic characteristic of malignant tumours and this 
hallmark is strictly intertwined with the continuous evolutionary pressure which selects the 
neoplastic cells that best fit in a specific anatomic compartment or timepoint during the course of 
disease, also because of external variables, such as ongoing treatments. Brastianos et al. (2015), 
showed that more than 50% of BMs harbour private molecular alterations (compared to the primary 
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tumour or extra-CNS lesions) which are potentially actionable.[82] These data suggest that, to offer 
the optimal treatment to these patients, BM sampling is necessary to fully recapitulate tumour 
heterogeneity; since surgical resection of BMs is not indicated in most cases, liquid biopsy could help 
overcome this limitation. 
Neoplastic meningitis (NM) is a specific type of secondary CNS involvement which is characterized by 
the spread of neoplastic cells across the leptomeninges and their circulation through the CSF. 
Definitive diagnosis is based upon cytological demonstration of malignant cells in the CSF, but 
sensitivity is limited and thus diagnosis usually relies on supporting clinical and neuroimaging 
findings.[83] Liquid biopsy could be a valuable diagnostic/profiling tool also in this setting. 
 
Circulating cell-free nucleic acids analysis 
The possibility of detecting tumour-derived cfDNA in patients with secondary CNS involvement has 
long been reported,[1] but only during the last few years this approach has received specific 
consideration as a potential tool for the routine care of patients.[20, 21, 36, 84-96] Most data have 
been obtained in NM from non-small-cell lung carcinoma (NSCLC), but studies on breast 
carcinoma[1], melanoma[89, 97] and secondary haematological malignancies[96] have also been 
reported (Table 2). 
cfDNA analysis proved a quite high overall sensitivity as a diagnostic tool for BMs or NM from solid 
tumours, ranging from 40% to 100%, but sample sizes of the available studies are still limited. 
Nevertheless, if we compare this tool with traditional cytology (the gold-standard for NM diagnosis 
at present),[98] cfDNA appears to be superior (Table 2). Another intrinsic advantage of liquid biopsy 
compared with cytology is that it allows tumour molecular profiling, while cytology can only provide 
a diagnostic confirmation.  
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With respect to the variables potentially affecting liquid biopsy yield, the type of CNS involvement 
should be considered. BMs may have limited contact with CSF, especially when dealing with a single 
or few lesions in a supratentorial intraparenchymal location. Conversely, tumour cells circulation in 
the CSF is a hallmark of NM, and thus a higher sensitivity can be expected in the latter condition. The 
results of Yang et al. (2014)[87] and Pentsova et al. (2016)[21] support these considerations, 
although De Mattos-Arruda et al. (2015)[20] and Pan et al. (2015)[36] were able to identify tumour 
cfDNA in all BMs cases (Table 2). 
As for primary CNS tumours, the most pressing question is choice of the source for cfNAs (or of other 
analytes). Blood or other easily accessible body fluids (like saliva or urine) would obviously be 
preferable, but they may not be representative of CNS-restricted lesions (Table 2). Some important 
considerations stem from the available data: i) a negative result may be obtained from blood-based 
liquid biopsy even when active disease is present within the CNS and this is an important concern 
when dealing with minimal residual disease monitoring; ii) even if we find alterations in blood-based 
liquid biopsy, these could be unrepresentative of the CNS disease. 
Within the possible practical applications of liquid biopsy in this setting, CSF testing in patients with 
CNS involvement by non-small cell lung carcinoma (NSCLC) seems one of the most promising, 
mirroring the already widespread practice of blood-based testing to promptly detect emerging 
resistance-associated mutations in extra-CNS NSCLC. As recently shown by Nanjo et al., the specific 
detection of the EGFR T790M mutation in CSF cfDNA was associated with clinical efficacy of 
treatment with osimertinib, a third-generation EGFR tyrosine kinase inhibitor developed to 
overcome T790M-induced resistance.[99] Conversely, in patients with positive CSF liquid biopsy, but 
without EGFR T790M detection, no response to treatment was observed. 
Last, it is worth pointing out that the significant differences observed between studies may depend 
on the wide range of techniques that have been tested so far. This variability should be addressed in 
future studies. 
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Circulating tumour cells and other approaches 
The presence of common membrane markers, like EpCAM, significantly helps CTCs collection in 
secondary CNS tumours, but alternative strategies are also possible.[100] As a diagnostic tool, CSF 
CTCs proved to be superior to traditional cytology[101]; moreover, the possibility of using this 
approach also for molecular profiling has been demonstrated. Magbanua et al. (2013 and 2014)[85, 
86] and Jiang et al. (2017)[91] were able to assess copy number and mutational profile of CSF CTCs in 
metastatic breast and lung cancer, respectively. Similar to cfNAs analysis, CTCs collection by blood-
derived liquid biopsy was not possible or showed a low yield in cases with CNS restricted disease. 
Best et al. (2015) showed that analysis of tumour educated platelets in patients with BMs allows 
identification of primary tumour type in 70% of samples.[15] Moreover, blood components indices 
(like white blood cells or platelets values and ratios) may harbour prognostic significance in patients 
with BMs[102]: this finding can be expected considered the role played by the systemic immune 
system in BM development.[103] 
Finally, EVs analysis in secondary CNS tumours is especially intriguing not only as a 
diagnostic/profiling tool, but also as a prognostic assay. Multiple studies suggested that tumour-
derived EVs may play an active role in creating a pro-metastatic niche in distant tissues[104], 
including the CNS.[10, 105] Thus, EVs characterization could allow to estimate the metastatic 
potential of a tumour and, possibly, to devise therapeutic strategies capable of hampering this 
process even before BMs are established. 
 
Future perspectives 
The recent technological advancements paired with the growing importance of molecular profiling in 
CNS neoplasms can explain the far-reaching results achieved in just the last few years regarding 
liquid biopsy use in CNS tumours.[106, 107]  
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The ever-increasing reliance on molecular traits for proper classification of primary CNS tumours will 
favour the clinical adoption of liquid biopsy as a routine diagnostic tool in selected cases, for 
example when surgical resection is not possible. Conversely, resection and histological examination 
will probably remain the cornerstone diagnostic approach if feasible, considered its therapeutic 
relevance and the risk of diagnostic pitfalls due to overlapping molecular features even between 
significantly different tumour entities [for example, a pilocytic astrocytoma (grade I) can rarely 
harbour the H3 K27M mutation which is characteristic of diffuse midline gliomas (grade IV)]. 
Moreover, a tissue sample is needed for whole genome or proteomic studies which are now 
increasingly warranted in translational/clinical research protocols. 
Liquid biopsy could instead represent a game-changing development for disease follow up 
considering that repeated surgical sampling is not feasible in CNS tumours. Its first implementation, 
in this setting, could probably be as a companion tool for disease monitoring and tumour burden 
quantification: liquid biopsy data could help resolve conflicting clinical and radiological findings, for 
instance when dealing with a suspected pseudo-progression. The following step could be the 
longitudinal assessment of tumour heterogeneity: for example, patients with IDH-mutant diffuse 
gliomas can have very long disease courses characterized by a progressive increase of tumour 
malignancy. Liquid biopsy could enable prompt detection and molecular characterization of disease 
progression, allowing optimisation of clinical management. Nevertheless, the relevance of liquid 
biopsy in this setting will ultimately depend on the identification of significant, actionable, 
prognostic and/or predictive markers. 
The same considerations apply to secondary neoplasms, but special caution should be applied when 
dealing with synchronous intra- and extra-CNS disease progression, since blood-derived results could 
be uninformative of the CNS disease. Nevertheless, the outcome of patients with BMs has 
dramatically changed in the last few years thanks to the newly available targeted treatments,[108] 
thus liquid biopsy is expected to become a mandatory assessment in an increasing number of 
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tumour types and disease settings for optimizing treatment decisions and prompt detection of 
resistance-associated mutations. 
 
Conclusion 
In the coming years, liquid biopsy will probably become a common tool for the diagnosis and follow 
up of both primary and secondary CNS tumours. For research purposes, liquid biopsy will be a 
cornerstone to determine longitudinal changes in the molecular profile of tumours, thus improving 
our knowledge of tumour resistance/progression mechanisms. Further studies, evaluating larger, 
prospective series, are needed to evaluate technical variabilities, validate its use in specific disease 
settings and, most importantly, to assess which is the ultimate clinical benefit for patients with CNS 
tumours. 
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Figure legend 
Fig 1 CSF sampling for liquid biopsy. CSF, usually sampled by lumbar puncture, allows gathering of 
multiple tumour components which can be submitted to a wide range of molecular tests. 
Fig 2 Liquid biopsy possible analytes and relevant assays. Different tumour components can be 
collected in liquid biopsy sources (blood or CSF) allowing a wide range of analyses. 
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Table 1. Studies investigating circulating cfDNA in primary CNS tumours. 
 
 Tumour Positive CSF 
cytology 
Positive CSF 
molecular profiling 
Positive blood 
molecular 
profiling 
Rhodes CH et 
al., J 
Neuropathol 
Exp Neurol 
1994 
Glioblastoma ND/NR 1/1 (100%) ND/NR 
Rhodes CH et 
al., Am J Clin 
Pathol 1995 
Glioblastoma ND/NR 1/1 (100%) ND/NR 
Boisselier B et 
al., Neurology 
2012 
Glioma (low 
grade=8, high 
grade=17) 
ND/NR ND/NR Low grade: 3/8 
(37.5%) 
High grade: 12/17 
(70.6%) 
Salkeni MA et 
al., J 
Neurooncol 
2013 
Glioblastoma ND/NR ND/NR 3/3 (100%) 
Bettegowda 
et al., Sci 
Transl Med 
2014 
Glioma (n=27) 
Medulloblastoma 
(n=14) 
ND/NR ND/NR Glioma: <10% 
Medulloblastoma
: <50% 
Pan W et al., 
Clin Chem 
2015 
Meningioma (n=1) 
Schwannoma (n=1) 
ND/NR Meningioma: 1/1 
(100%) 
Schwannoma: 0/1 
(0%) 
Meningioma: 0/1 
(0%) 
Schwannoma: 0/1 
(0%) 
De Mattos-
Arruda L et 
al., Nat 
Commun 
2015 
Glioblastoma (n=4) 
Medulloblastoma 
(n=2) 
ND/NR Glioblastoma: 4/4 
(100%) 
Medulloblastoma: 
2/2 (100%) 
Glioblastoma: 0/4 
(0%) 
Medulloblastoma
: 0/2 (0%) 
Wang Y et al., 
Proc Natl 
Acad Sci USA 
2015 
Low grade glioma 
(n=8) 
High grade glioma 
(n=13) 
Ependymoma 
(n=7) 
Medulloblastoma 
(n=6) 
Other low grade 
tumour (n=1) 
ND/NR Low grade glioma: 
6/8 (75%) 
High grade glioma: 
13/13 (100%) 
Ependymoma: 5/7 
(71%) 
Medulloblastoma: 
5/6 (83%) 
Other low grade 
tumour: 1/1 
(100%) 
ND/NR 
Pentsova EI et 
al., J Clin 
Glioma (n=8) 
Ependymoma 
Glioma: 0/8
Ependymoma: 0/1 
Glioma: 6/8 (75%)
Ependymoma: 0/1 
ND/NR 
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Oncol 2016 (n=1) (0%)
Connolly ID et 
al., J 
Neurooncol 
2017 
Ependymoma 
(n=3) 
ND/NR 0/3 (0%) 0/3 (0%) 
Huang TY et 
al., Acta 
Neuropathol 
Comm 2017 
Diffuse midline 
glioma (n=5) 
ND/NR 4/5 (80%) ND/NR 
Martìnez-
Ricarte F et 
al., Clin 
Cancer Res 
2018 
High grade glioma 
(n=15) 
Low grade glioma 
(n=5) 
ND/NR High grade glioma: 
15/15 (100%) 
Low grade glioma: 
2/5 (40%) 
ND/NR 
Pan C et al., 
Acta 
Neuropathol 
2018 
Brainstem glioma ND/NR 39/40 (98%) 3/8 (38%) 
Panditharatn
a E et al., Clin 
Cancer Res 
2018 
Diffuse midline 
glioma 
ND/NR 24/27 (89%) 34/40 (85%) 
Hiemcke-Jiwa 
LS et al., 
Hematol 
Oncol 2018 
Lymphoplasmacyti
c lymphoma (n=6) 
PCNSL (n=1) 
Lymphoplasmacyti
c lymphoma: 2/6 
(33%) 
PCNSL: 1/1 (100%) 
Lymphoplasmacyti
c lymphoma: 5/6 
(83%) 
PCNSL: 1/1 (100%) 
ND/NR 
Miller AM et 
al., Nature 
2019 
Diffuse glioma 
(grade II-III-IV) 
7/80 (9%)
CSF cytology not 
available in 5 cases 
42/85 (49%) 3/19 (16%) 
 
Notes: i) CSF molecular profiling was considered positive if at least one tumour mutation was 
detected in cfDNA, but in some cases only a subset of alterations was detected compared to tissue 
samples; ii) Cases with negative/not available tissue profiling and negative liquid profiling were 
excluded. Conversely, cases with positive CSF despite negative or untested primary were considered; 
iii) Atypical cells were considered positive in terms of CSF cytology evaluation. CNS: central nervous 
system; CSF: cerebrospinal fluid; ND/NR: not done/not reported, PCNSL: primary central nervous 
system lymphoma. 
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Table 2. Studies investigating circulating cfDNA in secondary CNS tumours from solid neoplasms. 
 Primary 
tumour 
Type of CNS 
involvement 
Positive CSF 
cytology 
Positive CSF 
molecular 
profiling 
Positive 
blood 
molecular 
profiling 
Rhodes CH et al., J 
Neuropathol Exp 
Neurol 1994 
Breast NM ND/NR 1/1 (100%) ND/NR 
Swinkels DW et al., 
Clin Chem 2000 
NSCLC NM 0/2 (0%) 2/2 (100%) ND/NR 
Shingyoji M et al., J 
Thorac Oncol 2011 
NSCLC NM 10/21 
(47.6%) 
13/21 (61.9%) ND/NR 
Yang H et al., J Mol 
Diagn 2014 
NSCLC BM and NM ND/NR BM: 2/5 (40%) 
NM: 4/4 
(100%) 
ND/NR 
De Mattos-Arruda L et 
al., Nat Commun 2015 
Breast and 
lung 
BM and NM BM: 13/24 
(54.2%) 
NM: 1/3 
(33%) 
BM: 17/17 
(100%) 
NM: 3/3 
(100%) 
0% in CNS 
restricted 
disease 
Pan W et al., Clin 
Chem 2015 
Mixed BM and NM BM: ND/NR
NM: 2/2 
(100%) 
BM: 5/5 
(100%) 
NM: 1/1 (total 
DNA was 
analysed) 
BM: 3/5, 2/3 
with also 
extra-CNS 
progression 
NM: ND/NR 
Sasaki S et al., Respir 
Investig 2016 
NSCLC NM 2/7 (28.6%) 7/7 (100%) 0/3 (0%) 
Li Y et al., J 
Neurooncol 2016 
Melanoma NM 1/1 (100%) 1/1 (100%) 0/1 (0%) 
Pentsova EI et al., J 
Clin Oncol 2016 
Mixed BM and NM BM: ND/NR
NM: 3/3 
(100%) 
BM: 17/24 
(70.8%) 
NM: 3/3 
(100%) 
ND/NR 
Zhao J et al., Cancer 
Chemother Pharmacol 
2016 
NSCLC NM 7/7 (100%) 2/7 (28.6%), 
1/2 with also 
extra-CNS 
progression 
Marchiò C et al., 
Neuro Oncol 2017 
NSCLC NM 2/2 (100%) 2/2 (100%) 0/2 (0%) 
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Siravegna G et al., 
ESMO Open 2017 
Breast NM ND/NR 1/1 (100%) 1/1 (100%), 
but showed 
decreasing 
mutant allele 
frequencies 
despite CNS 
disease 
progression 
Huang W et al., Case 
Rep Oncol 2018 
CUP NM 1/1 (100%) 1/1 (100%) ND/NR 
Li et al., Ann Oncol 
2018 
NSCLC NM 18/28 (64%) 28/28 (100%) 19/26 
(73.1%) 
Ballester LY et al., J 
Neuropathol Exp 
Neurol 2018 
Melanoma NM 3/3 (100%) 2/3 (67%) ND/NR 
Nanjo S et al., Br J 
Cancer 2018 
NSCLC NM 5/13 (38%) 5/13 (38%) ND/NR 
 
Notes: i) CSF molecular profiling was considered positive if at least one tumour mutation was 
detected in cfDNA, but in some cases only a subset of alterations was detected compared to tissue 
samples; ii) In many cases NM was present together with BM: these cases were considered together 
with NM only cases; iii) Cases with negative/not available tissue profiling and negative liquid 
profiling were excluded. Conversely, cases with positive CSF despite negative or untested primary 
were considered; iv) Atypical cells were considered positive in terms of CSF cytology evaluation. BM: 
brain metastasis; CNS: central nervous system; CSF: cerebrospinal fluid; CUP: cancer of unknown 
primary; NM: neoplastic meningitis; NSCLC: non-small cell lung cancer; ND/NR: not done/not 
reported.  
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